Introduction
Bisphenol A (BPA; CAS 80-05-7) is one of the highest production volume chemicals worldwide, with annual production exceeding 3 million metric tons. BPA is used in the production of polycarbonate plastics, epoxy resins, and non polymer additives to other plastics. It is used extensively in the manufacturing of common consumer products and goods such as food containers, metal cans (as a protective coating), beverage and baby bottles, receipt paper, and water pipes (Vandenberg et al. 2007) . Human exposure to BPA from diet, inhalation, and other exposure routes has been well documented (Geens et al. 2012; Vandenberg et al. 2007) . BPA has been detected in > 90% of individuals in various sample populations (Vandenberg et al. 2010) .
BPA is an estrogenic endocrine-disrupting chemical (EDC) with potentially adverse impacts on human health (DiamantiKandarakis et al. 2009) . A large body of evidence has linked BPA exposure to abnormalities such as obesity, diabetes, and disorders of the reproductive and immune systems. Growing evidence also suggests that BPA may have adverse impacts on the cardio vascular system. Several epidemiological studies have reported an associaton between higher human BPA exposure and cardiovascular diseases, including coronary and peripheral arterial diseases (Lang et al. 2008; Melzer et al. 2010 Melzer et al. , 2012 Shankar et al. 2012) . Recently, we reported that acute exposure to environ mentally relevant low doses of BPA promoted arrhythmogenic-triggered activities in cardiac myocytes from female rodent hearts (Belcher et al. 2012; Yan et al. 2011) . The pro arrhythmic action of BPA is manifested as increased frequency of ventricular arrhythmias under stress conditions (Yan et al. 2011) , as well as increased duration and severity of ventricular arrhythmias following ischemic injury in female rodent hearts (Yan et al. 2013) . We found that alterations of myocyte Ca 2+ (calcium ion) handling, including elevated sarco plasmic reticulum (SR) Ca 2+ spontaneous release (or Ca 2+ leak) and SR Ca 2+ reuptake, are a key mechanism under lying the pro arrhythmic action of BPA (Gao et al. 2013; Yan et al. 2011) . These findings point to the potential cardio vascular toxicity of BPA.
Previously we reported that the rapid effect of BPA on the contractility of female cardiac myocytes is characterized by a nonmonotonic dose response (Belcher et al. 2012) . A non monotonic dose-response curve is one that has a point of inflection where the curve slope switches sign from positive to negative or vice versa. Numerous examples of non monotonic dose responses have been reported for a range of EDCs and hormones at the gene expression, cell, tissue/organ, animal, and population levels (see Vandenberg et al. 2012 for a comprehensive review). This pharmaco dynamic property is of critical importance to the assess ment of toxicity of BPA and other EDCs (Fagin 2012; Myers et al. 2009 ). The Chapel Hill BPA expert panel identified the need for investigation of the mechanisms under lying non monotonic dose responses as one of the major data gaps in BPA research (Wetherill et al. 2007 ). In the present study, we further define the dose-response properties of BPA in the heart, and elucidate the under lying mechanism of the non monotonicity of BPA's cardiac impact.
Background:
The need for mechanistic understanding of non monotonic dose responses has been identified as one of the major data gaps in the study of bisphenol A (BPA). Previously we reported that acute exposure to BPA promotes arrhythmogenesis in female hearts through alteration of myocyte Ca 2+ handling, and that the dose response of BPA was inverted U-shaped. oBjective: We sought to define the cellular mechanism underlying the non monotonic dose response of BPA in the heart. Methods: We examined rapid effects of BPA in female rat ventricular myocytes using video-edge detection, confocal and conventional fluorescence imaging, and patch clamp. NJ, USA) to eliminate possible corn-based myco estrogen exposure. Room conditions included a 14-hr-light/10-hr-dark cycle, with lights on at 0600 hours. All animals were fed ad libitum with Teklad 2020 diet (Harlan Laboratories Inc., Indianapolis, IN, USA), which contains no soybean meal, alfalfa, or animal products that may introduce uncontrolled levels of estrogenic compounds. Sterile drinking water was generated by a dedicated water purification system (Millipore Rios 16 with ELIX UV/Progard 2) that reduces oxidizable organics to < 1% of source levels. Drinking water was dispensed from glass water bottles. A total of 70 animals were used in this study.
Analysis of myocyte mechanics and Ca 2+ handling. Ventricular myocytes from female rat hearts were enzymatically dissociated using Langendorff perfusion, as previously described (Yan et al. 2011 (Yan et al. , 2013 . Isolated myocytes were then suspended in 1.0 mm Ca 2+ -Tyrode solution. We analyzed myocyte contraction, after-contraction, and Ca 2+ transient and spark as previously described (Yan et al. 2011) . Briefly, myocytes were excited by field stimulation with 2-msec 1.5× threshold pulses at a rate of 0.5 Hz. Steady-state myocyte shortening was examined using a videoedge detector (Crescent Electronics, Sandy, UT, USA). After-contraction was measured using stimulation of 2 msec 1.5× threshold pulses at a rate of 2 Hz for 8 sec. To measure Ca 2+ spark, isolated ventricular myocytes were loaded with fluo-4 acetoxymethyl ester (5 μM; Molecular Probes, Eugene, OR, USA) and imaged with a Zeiss LSM 710 inverted confocal microscope (Carl Zeiss Microscopy, LLC, Thornwood, NY, USA) with an excitation wave length of 488 nM. Signals were measured with line-scan imaging at 3.07-msec intervals, with each line comprising 512 pixels spaced at 0.056 mm. Image processing and data analysis were performed as previously described (Yan et al. 2011) . To measure Ca 2+ transients, fluorescence signals were measured from fluo-4 loaded myocytes using a Nikon TE 2000 microscope and an InCyt Standard PM photometry system (Intracellular Imaging, Cincinnati, OH, USA). Experiments were performed at room temperature (24°C).
Patch clamp recording of I CaL (L-type Ca 2+ current). The I CaL was recorded at room temperature (24°C) using the whole-cell patch clamp technique, as previously described (Yan et al. 2011) . After the membrane was ruptured, cells were clamped at -50 mV for 5 min to allow dialysis of the intra cellular solution and stabilization of the Ca 2+ currents before measurement began. Data collection and analysis were performed using PCLAMP 9 software (Molecular Devices, Sunnyvale, CA, USA).
Western blotting. Western blotting experiments were performed as previously described (Gao et al. 2013) . Briefly, isolated female ventricular myocytes were treated with BPA for the indicated length of time, collecte, and snap-frozen in liquid nitrogen. Proteins were extracted with 1× Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA, USA) supplemented with protease inhibitors and phosphatase inhibitors. Equal amounts of protein samples from each treatment group were separated by SDS-PAGE and transferred to a nitro cellulose membrane (Bio-Rad, Hercules, CA, USA). The membrane was then blocked with 5% non-fat milk in phosphate-buffered saline-0.1% Tween, followed by incubation with primary and secondary antibodies. We used ECL™ Western Blotting Analysis System (GE Healthcare, Buckinghamshire, UK) for developing the membrane. We used the following antibodies: anti-phospholamban phospho threonine-17 (pThr17-PLN) and anti-phospholamban (anti-PLN), both from Badrilla (Leeds, UK); and horseradish peroxidase-conjugated anti-mouse and antirabbit secondary ant bodies (Cell Signaling Technology).
Statistical analysis. We conducted statistical analysis using an unpaired t-test or by one-way analysis of variance (ANOVA) with differences between treatment groups assessed using a multiple comparison posttest. Frequency of events (e.g., percentage of myocytes with after-contractions) was analyzed using a chi-square test. We considered p < 0.05 the minimal level of statistical significance for differences in values. Data were analyzed using SigmaPlot (Systat Software Inc., San Jose, CA, USA) and Excel (Microsoft, Redmond, WA, USA).
Results
Rapid actions of BPA in cardiac myocytes have non monotonic dose responses. We examined the concentration-dependent effect of BPA on Ca 2+ transient in female rat ventricu lar myocytes. BPA rapidly (~ 5 min) increased the amplitude of the Ca 2+ transient at low BPA doses (10 -10 to 10 -8 M), and this stimulatory effect diminished at micro molar doses ( Figure 1A,B) ; the dose-response curve was inverted U-shaped with the most efficacious concentration being 10 -8 M ( Figure 1B ). Previously we showed that BPA rapidly promoted the development of spontaneous excitation (i.e., triggered activities) in female cardiac myocytes (Yan et al. 2011) . The stimulatory effect of BPA on triggered activities was only notable in the nanomolar dose range but not at higher doses ( Figure 1C) , producing a dose-response curve with pronounced nonmonotonicity ( Figure 1D ).
One mechanism of the non monotonic dose response of hormones and EDCs is general cyto toxicity (Vandenberg et al. 2012) ; this possibility was examined. Consistent with our previous findings (Belcher et al. 2012 ), 10 -8 M BPA rapidly stimulated the contraction of female myocytes, and this stimulatory effect diminished at the micro molar concentration ( Figure 1E ). Myocytes that were pre treated with 10 -6 M BPA followed by a wash responded robustly to subsequent exposure to 10 -8 M BPA ( Figure 1F ). In addition, the β-adrenergic agonist isoproterenol produced marked stimulatory effect in the presence of 10 -6 M BPA. These results suggest that the diminished response of myocytes to micro molar concentrations of BPA is not due to nonspecific cytotoxicity of BPA at higher doses.
BPA alters individual elements of myocyte Ca 2+ handling with monotonic dose responses. BPA promotes arrhythmogenesis and enhances myocyte contraction via alteration of myocyte Ca 2+ handling (Yan et al. 2011) . To understand the mechanism of the nonmonotonicity of BPA's rapid actions in cardiac cells, we examined the dose-dependent impact of BPA on the individual elements of the myocyte Ca 2+ handling process.
Effect on Ca 2+ spark. Increased Ca 2+ release and Ca 2+ leak from the SR play a central role in the impact of BPA on arrhythmo genesis and myocyte mechanics (Yan et al. 2011) . Diastolic Ca 2+ release from the SR through the ryanodine receptors was measured as frequency of Ca 2+ sparks (Cheng et al. 1993) . Interestingly, unlike the non monotonic dose responses observed at the myocyte level, BPA's impact on SR Ca 2+ release was monotonic (Figure 2 ). Increasing concentrations of BPA over the dose range of 10 -10 to 10 -5 M progressively increased Ca 2+ spark frequency (Figure 2A,B) . The doseresponse curve had a classic monotonic shape with median effective concentration (EC 50 ) of 0.81 nM and a maximum increase of 209.7% ( Figure 2C) .
Effect of BPA on SR Ca 2+ reuptake. BPA rapidly increases SR Ca 2+ reuptake in female rat myocytes (Yan et al. 2011) . In rodent cardiac myocytes, SR reuptake accounts for most (> 90%) of Ca 2+ removal from the cytosol during relaxation (Bers 2002) ; therefore, the rate of decline of the Ca 2+ transients can be used as an index of SR Ca 2+ reuptake. Whereas the effect of BPA on Ca 2+ transient amplitude was inverted U-shaped ( Figure 3A , top), normaliza tion of the Ca 2+ transient traces revealed that increasing Figure 3A, bottom) , producing a monotonic dose-response curve ( Figure 3B ). The dose response had an EC 50 of 0.15 nM and a maximum increase of 37.3% ( Figure 3C ).
Through its inhibition of sarco/ endoplasmic reticulum Ca 2+ -ATPase (SERCA), PLN is the central regulator of SR Ca 2+ reuptake. PLN can be phosphorylated by both protein kinase A and Ca 2+ / calmodulindependent protein kinase II (CAMKII) at serine 16 and threonine 17, respectively. Phosphorylation of PLN releases its inhibition on SERCA, thereby increasing Ca 2+ reuptake into the SR (Kranias and Hajjar 2012) . Because BPA has been shown to influence SR Ca 2+ reuptake via increasing CAMKII phosphorylation of PLN at threonine 17 (Gao et al. 2013) , we examined the dose-dependent effect of BPA (2-min exposure) on CAMKII phosphorylation of PLN. Increasing concentrations of BPA over the dose range of 10 -12 M to 10 -6 M progressively increased phosphorylation of PLN at the CAMKII site ( Figure 3D ). Based on the known regulatory mechanism of SR Ca 2+ reuptake, this dosedependent effect of BPA on PLN phosphorylation should increase SERCA activity, and likely accounts for the monotonic effect of BPA on SR Ca 2+ reuptake. Effect on I CaL. The stimulatory, monotonic effects of BPA on SR Ca 2+ release and reuptake were countered by an inhibitory action of BPA on the L-type Ca 2+ current, particularly at higher concentrations ( Figure 4A ). The dose-response curve for the inhibition of I CaL was, again, monotonic ( Figure 4B) , with an EC 50 of 27.4 nM and a maximum inhibition of 43%. The current-voltage relationship of I CaL was not changed by BPA.
Interestingly, although the overall effect of BPA on I CaL was one of suppression, we noticed a small but consistent stimulation of the current at lower BPA concentrations (10 -12 M) ( Figure 4C ). The average increase of I CaL at 10 -12 M BPA was 4.5%, which occurred within minutes of exposure.
BPA's rapid actions are mediated by ERβ signaling. Previously we hypothesized that the opposing actions of estrogen receptor (ER) α and ERβ contribute to the non monotonic dose response of BPA in the heart (Belcher et al. 2012 ). Contrary to this hypothesis, in the presence of MPP, an ERα-selective blocker, the non monotonicity of the dose-response curve was unchanged ( Figure 5A) ; ERβ blockade with PHTPP largely abolished the rapid effect of BPA on contractility ( Figure 5B) .
We also examined the role of ERβ in mediating the effects of BPA on individual Ca 2+ cycling processes. ERβ blockade with PHTPP completely abolished the stimulatory effect of BPA on Ca 2+ spark frequency ( Figure 5C ,D) and blocked effects of BPA on the amplitude and decline kinetics of Ca 2+ transient ( Figure 5E,F) . Similarly, PHTPP abolished the inhibitory effect of BPA (10 -5 M) on I CaL ( Figure 5G,H) . Thus, ERβ signaling played a dominant role in mediating BPA's non monotonic dose response in cardiac myocytes, as well as in its actions on individual Ca 2+ cycling processes.
Suppression of I CaL contributes to the nonmonotonic effects of BPA. To test the hypothesis that the inhibitory effect of high-dose BPA on I CaL produces the non monotonic dose responses, we used the selective I CaL blocker nifedipine to mimic the inhibition by BPA. The stimulatory effects of 10 -8 M BPA on SR Ca 2+ release and reuptake were near or at saturation (Figures 2 and 3) , whereas BPA only inhibited I CaL by 11% (Figure 4) . At 2 × 10 -7 M, the dose of nifedipine used in our experiments, nifedipine blocked I CaL by 39% ( Figure 6A,B) , which is consistent with the reported median inhibitory concentration (IC 50 ) of nifedipine of 0.3 μM (Shen et al. 2000) . We examined the dose response of BPA over the dose range of 10 -12 to 10 -8 M as well as 10 -8 M BPA plus nifedipine. Nifedipine plus 10 -8 M BPA reproduced the inverted U-shaped dose responses as measured by both myocyte contractility ( Figure 6C,D) and incidence of triggered activities ( Figure 6E,F) . Thus, the monotonic and stimulatory effects of BPA on SR Ca 2+ release and reuptake, plus the inhibitory effect of higher-dose BPA on I CaL , are sufficient to produce the nonmonotonic dose responses of BPA in female rat cardiac myocytes.
Discussion
Defining the non monotonic dose responses of EDCs is of both scientific interest and We show that acute exposure to low doses of BPA (≤ 10 -8 M) had significant impact on arrhythmo genesis and the mechanics of female cardiac myocytes, and that the dose responses of the rapid impact of BPA are nonmonotonic. The non monotonicity is produced by multiple monotonic effects on individual cellular Ca 2+ handling processes through ERβ-mediated signaling ( Figure 6G ). Our results add to a growing body of evidence demonstrating the non monotonic responses of EDCs and provide mechanistic insights into the pharmaco dynamics of BPA's actions. Non monotonic dose responses of EDCs and hormones have been well documented and are likely a common phenome non of EDCs (Vandenberg et al. 2012 ). Nevertheless, their existence and significance have been disputed (Rhomberg and Goodman 2012) , citing the lack of statistical significance in some studies and attributing the observations to random dose-by-dose fluctuations and high signal-to-noise ratio. In addition, existing evidence of non monotonicity has been faulted for involving only quantitative continuous end points and lacking all-or-none biological events. The lack of mechanistic understanding of the link between quantitatively continuous effects of EDCs and changes in incidence rates of distinct diseases is viewed as a weakness. We assessed the dose response of BPA in cardiac cells using multiple end points, including myocyte contraction, Ca 2+ dynamics, and arrhythmogenesis, using separate and independent measurement assays; each produced dose responses with marked non monotonicity. The response measured at 10 -6 M BPA for each of the end points showed clear and statistically significant (p < 0.01) declines compared with 10 -8 M; 10 -6 M BPA was not statistically different (p > 0.2) compared with control (Figure 1 ). Given the consistency among multiple end points, statistical significance of the results, and reproducibility of these nonmonotonic events from previous studies (Yan et al. 2011) , we consider it unlikely that the observed non monotonic dose responses are attributable to random fluctuation. Of particular significance is the arrhythmo genesis end point (i.e., incidence of triggered activity). Triggered activities are aberrant spontaneous excitations of cardiac myocytes and are wellrecognized as one of the key arrhythmogenic mechanisms in the heart (Pogwizd and Bers 2004) ; therefore, they could be considered a toxicologically relevant end point. The presence or absence of triggered activity is clearly an all-or-none event and was measured as such in our study. The pronounced inverted U-shape of BPA's effect on this all-or-none end point is evident. Other examples of BPA impacting all-or-none events with nonmonotonic dose responses include the presence or absence of tumor and metastases (e.g., Jenkins et al. 2011) . Thus, the non monotonic dose response of BPA is not limited to quantitative continuous end points.
Growing evidence has provided increasing under standing of the mechanisms that generate the non monotonic dose response of EDCs. The known mechanisms are diverse and have been reviewed in a number of articles (Myers et al. 2009; Vandenberg et al. 2012; Watson et al. 2010) . Examples of these mechanisms include actions of different types of receptors (e.g., ERα and ERβ) with opposing signaling effects, cell subpopulation-specific and opposite responses to hormone actions, cytotoxicity associated with higher hormone doses resulting in decreased responses, signaling through parallel pathways with different temporal activation patterns, receptor desensitization, and receptor down-regulation at higher doses. A range of other xeno biotics are capable of producing non monotonic effects due to non specific mechanisms of action. Here, we describe a distinct mechanism in cardiac myocytes that involves signaling of a single receptor, ERβ, that results in multiple monotonic effects on individual elements of the myocyte Ca 2+ handling process ( Figure 6G ). Previously, we showed that the rapid effect of BPA on cardiac arrhythmo genesis and mechanics is mediated by its impact on myocyte Ca 2+ handling; in particular, increased diastolic SR leak plays a key role in the arrhythmogenic effect of BPA (Yan et al. 2011 ). The present results show that BPA rapidly increased SR Ca 2+ release/ leak and SR reuptake with monotonic dose responses. Opposing this stimulatory effect is the monotonic suppression of I CaL at micromolar doses. Based on known mechanisms of cardiac Ca 2+ handling, suppression of I CaL also reduces Ca 2+ -induced Ca 2+ release from the SR, resulting in reduced Ca 2+ transient amplitude and myocyte contraction. Suppression of Ca 2+ influx through I CaL may reduce intracellular Ca 2+ , thereby reducing the development of triggered activities, particularly delayed after depolarizations (Pogwizd and Bers 2004) . The exact impact of I CaL inhibition in the presence of enhanced SR Ca 2+ cycling is complex and influenced by feedback regulatory mechanisms (Eisner et al. 2013) . To test the role of I CaL suppression in generating the decline phase of the inverted U-shaped dose-response curve, we observed that mimicking BPA's suppression of I CaL with the Ca 2+ channel blocker nifedipine, at a dose that produces a percentage blockade of I CaL similar to that of high-dose BPA, reproduced the inverted U-shaped curve. We do recognize that the result of this experiment is confounded by the fact that we used 10 -8 M BPA (which produces a 10% blockade of I CaL ) plus nifedipine to mimic the effect of micromolar BPA, and that the over lapping effects of BPA and nifedipine on I CaL do not fully reproduce the effect of micromolar BPA. Nevertheless, the result qualitatively demonstrates that the non monotonic effect of BPA can be accounted in part by I CaL inhibition.
Suppression of I CaL by high-dose BPA is similar to that observed in response to high concentrations of 17β-estradiol (E 2 ), suggesting the possibility of a common mechanism. Several studies have shown that supra physiological E 2 (10-30 μM) partially suppresses I CaL in cardiac myocytes in multiple speci, including rat, human, and guinea pig (Berger et al. 1997; Kurokawa et al. 2008; Meyer et al. 1998; Nakajima et al. 1999 ). E 2 has been shown to suppress I CaL in guinea pig ventricular myocytes, with an IC 50 of 29.5 nM and a maximum suppression of 40% (Kurokawa et al. 2008 ), values that are remarkably similar to the dose response for the blockade by BPA. Such suppression of I CaL by high doses of estrogens, while of limited physiological relevance, may play a role in determining the dose-response properties of other estrogenic chemicals in the heart.
It has been shown both experimentally and computationally that non monotonic dose responses can be generated by the opposing actions of multiple receptors (Conolly and Lutz 2004; Vandenberg et al. 2012; Watson et al. 2010) . In previous studies we found that ERα and ERβ had opposing actions in cardiac myocytes (ERα rapid signaling had an inhibitory effect, whereas ERβ was stimula tory); thus, the rapid actions of BPA in female hearts are mediated by the stimulatory signaling of ERβ, and the counter balance of ERα versus ERβ results in the lack of observable response to BPA in male hearts (Belcher et al. 2012) . Indeed, we speculated previously that the opposing actions of ERα and ERβ generate the non monotonic dose response of BPA in the heart (Belcher et al. 2012 ). This, however, does not appear to be the case. As shown in Figure 5 , pharmacological blockade of ERβ largely abolished the rapid effect of BPA on contractility, whereas blockade of ERα had no detectable effect on the inverted U-shaped dose response. Although the sum of BPA's effects on multiple Ca 2+ handling processes is sufficient to account for the observed nonmonotonicity, the potential contribution of other mechanisms, such as receptor desensitization, were not examined in the present study and cannot be ruled out. In addition, the molecular/signaling mechanisms under lying BPA's impact on the Ca 2+ handling elements are unknown and remain to be elucidated.
Conclusion
The rapid effects of BPA on female rat cardiac myocytes were charac terized by non monotonic dose responses, as measured by multiple end points; the cellular mechanism of BPA's non monotonicity involves monotonic and opposing effects on multiple Ca 2+ handling processes, all mediated by ERβ signaling. The summation of these parallel effects generated an inverted U-shaped dose response, with the most efficacious dose around 10 -8 to 10 -9 M, coinciding with reported human exposure levels (Vandenberg et al. 2010 ) ( Figure 6G ).
